These results indicate that identified secondary metabolites can affect not only the Aβ production of SAD neurons, but also that of FAD neurons. Furthermore, to investigate whether secondary metabolites have different effects on Aβ production for each individual or for different pathological conditions, we evaluated the dose-dependency of Verrucarin A and Mer-A2026A by using four additional iPSCs established from two healthy controls, another SAD patient, and another familial AD patient with APP V717L mutation (APP-FAD)21 (Fig. S5). Here, APP is linked to Alzheimer disease.